Director at Asabys, where he joined in 2018. Guillem is primarily responsible for sourcing, executing, and managing investments, with a major focus in the firm’s health-tech portfolio. He is also leading Asabys’ deal structuring, transactions and negotiations. Guillem is an observer on the board of directors of Cara Care, Origo Biopharma, Psious and Sidekick Health.
Prior to joining Asabys, Guillem was the Portfolio Manager of the Life Sciences portfolio at Caixa Capital Risc for four years. Before that, he served at EY within the Transaction Advisory Services primarily focusing on PE and VC transactions.
Guillem holds a BBA with a major in finance from Universitat Pompeu Fabra (UPF).